INTRODUCTION

METHODS
RESULTS
 To the best of our knowledge, this is the first research initiative to conduct a systematic assessment to comprehensively assess if provisions and special considerations are provided to rare diseases / orphan drugs by various HTA bodies  The findings of this research initiative can serve as a compendium to understand the rare disease legislation in health technology assessment area in major markets governed by HTA bodies
STRENGTHS LIMITATIONS
 Most of the studied markets provide formal definitions of rare disease, and support access through leniency in trial design, sample and statistical analysis criteria, higher thresholds in justifying the economics of use, rapid drug approval, better market exclusivity, extended registration period, and tax benefits  Several markets without clear disease definition such as Canada, Mexico, Chile and Malaysia are in process of establishing formal disease definitions and discussing models for reimbursement  With populations exceeding 1 billion, China and India have no special legislations or considerations for rare diseases / orphan drugs. Limitations in healthcare coverage through the Public Payer, and lack of access to more traditional "non-orphan therapies" may render these markets considerably further behind in the consideration and adoption of orphan drugs  In parallel to developing the healthcare infrastructure, opportunities for significant development in rare disease area exists in Latin American and South East Asian countries  As evidence demonstrating the considerable mortality and morbidity benefit and outcomes of orphan drugs become evident, HTA systems and Payers need to become increasingly considerate of reimbursement opportunities and leniencies that can promote innovation while managing budget impact  Lack of considerations for rare diseases impacts access to the orphan drugs which negatively affects patients lives
DISCUSSION
REFERENCES
 Inherent to any systematic assessments, some studies may have gotten eliminated due to non-indexing on the literature database utilized  Some HTA body websites were not clear, and this many have lead to exclusion of some key content available as documents; also some data may have been missed during translation to English language  We conducted a systematic assessment of published studies, guidelines and recommendations by HTA bodies (websites) in 25 markets, which encompassed North America, Europe, Latin America, and Asia Pacific  Of the 25 HTA bodies assessed, 15 have special provisions for rare diseases / orphan drugs, 9 did not explicitly mention special considerations , while the remaining 1 do not provide any consideration.  Mexico: Regulations do not provide an "exhaustive body of law" for orphan drugs, and there is no regulation for "exclusivity"; There remains a need for regulatory incentives that promote investment for research and development of orphan drugs [8]
Asia-Pacific:
 Of 10 countries, five HTA bodies had special provisions and five HTA bodies did not report any specific considerations for rare diseases  Australia: "Rule of rescue", reserved for therapies targeting serious or fatal diseases with no alternatives, is applicable. According to the Australian Orphan Drug Program (1997), rare diseases receive rapid drug approval, market exclusivity, and assistance for approval and submission, which is reconsidered every 12 months [6, 9, 10]  Japan: According to Orphan Drug Regulation (1993), rare diseases receive tax incentive, evaluation and rapid drug approval, market exclusivity, assistance for approval and partial reimbursement of development costs; extended registration period [6]  South Korea: Drug Benefit Assessment Committee (DBAC) considers "essential drugs" to be those that fulfill the following criteria: no alternative treatments; use for severe, life-threatening diseases; use for a minority of patients who have rare diseases etc.; and proven to provide clinically meaningful improvement for patients. Strict HTA requirements are waived for rare diseases, although cost-effectiveness data are referenced [11, 12]  Taiwan: Health Promotion Administration and Taiwan FDA provides tax credits/reductions for clinical studies of rare diseases and provides fee reduction for marketing authorization applications, inspections and post-authorization activities. Orphan drugs can bypass the designation and NHI appraisal for listing and pricing to get into health care market [13] Special consideration provided by the HTA body Special consideration not provided by the HTA body Not found/not reported 
